Segment Disclosures (Details) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
segment
|
Jun. 30, 2024
USD ($)
|
|
| Segment Disclosures | ||||||
| Number of Reportable Segments | segment | 1 | |||||
| Total revenue | $ 836,000 | $ 778,000 | $ 1,704,000 | $ 1,398,000 | ||
| Cost of product revenues | 46,000 | 44,000 | 90,000 | 78,000 | ||
| Depreciation expense | 81,000 | 74,000 | 164,000 | 148,000 | ||
| Interest income (expense), net | 36,000 | (902,000) | (130,000) | (1,918,000) | ||
| Net loss | (19,363,000) | $ (18,755,000) | (15,980,000) | $ (13,463,000) | (38,118,000) | (29,443,000) |
| Partnership revenue | ||||||
| Segment Disclosures | ||||||
| Total revenue | 667,000 | 628,000 | 1,399,000 | 1,125,000 | ||
| Product revenue | ||||||
| Segment Disclosures | ||||||
| Total revenue | 169,000 | 150,000 | 305,000 | 273,000 | ||
| Single Reportable Segment | ||||||
| Segment Disclosures | ||||||
| Cost of product revenues | 46,000 | 44,000 | 90,000 | 78,000 | ||
| Personnel and consulting costs | 7,002,000 | 5,913,000 | 13,666,000 | 11,407,000 | ||
| Stock-based compensation | 3,250,000 | 2,761,000 | 6,215,000 | 5,349,000 | ||
| Depreciation expense | 81,000 | 74,000 | 164,000 | 148,000 | ||
| Other segment expenses | 2,544,000 | 2,716,000 | 5,170,000 | 5,283,000 | ||
| Interest income (expense), net | 36,000 | (902,000) | (130,000) | (1,918,000) | ||
| Net loss | (19,363,000) | (15,980,000) | (38,118,000) | (29,443,000) | ||
| Single Reportable Segment | Partnership revenue | ||||||
| Segment Disclosures | ||||||
| Total revenue | 667,000 | 628,000 | 1,399,000 | 1,125,000 | ||
| Single Reportable Segment | Product revenue | ||||||
| Segment Disclosures | ||||||
| Total revenue | 169,000 | 150,000 | 305,000 | 273,000 | ||
| Single Reportable Segment | Non-clinical development costs | ||||||
| Segment Disclosures | ||||||
| Development costs | 4,607,000 | 4,648,000 | 9,072,000 | 7,947,000 | ||
| Single Reportable Segment | Clinical development costs | ||||||
| Segment Disclosures | ||||||
| Development costs | $ 2,633,000 | $ 1,504,000 | $ 5,575,000 | $ 2,547,000 | ||
| X | ||||||||||
- Definition Represents the amount of development costs. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as nonoperating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|